gemcitabine + Jelmyto

Gemcitabine + Jelmyto is a combination regimen involving sequential or concurrent administration of two chemotherapeutic agents for the treatment of urothelial cancers, particularly upper tract urothelial carcinoma (UTUC). Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to cell death in rapidly dividing tumor cells. Jelmyto is a proprietary reverse thermal gel formulation containing mitomycin, which becomes semi-solid at body temperature to allow prolonged local exposure; mitomycin acts as an alkylating agent that crosslinks DNA and inhibits cancer cell proliferation. This combination aims to maximize local tumor control while preserving kidney function in patients with low-grade UTUC who are not candidates for surgery or wish to avoid nephroureterectomy[1][2][3]. The approach leverages the established efficacy of both agents—gemcitabine’s systemic cytotoxicity and Jelmyto’s chemoablative effect—to potentially improve outcomes over monotherapy.

Brand names

Jelmyto

Other names

gemcitabine and Jelmytogemcitabine plus Jelmytogemcitabine and mitomycin reverse thermal gel